Small logo Subscribe to leading news on impact investing. Learn More
The Brief Originals Dealflow Signals The Impact Alpha Impact Voices Podcasts Agents of Impact Open
What's Next Measure Better Investing in Racial Equity Beyond Aid Beyond Trade-offs Impact en las Americas New Revivalists Women Rising in India Operation Impact
Smarter Money Women Rising 2030 Finance Locavesting Inclusive Economy Regeneration Impact Tech New Power Geographies
Slack Conference Calls Events Contribute
The Archive ImpactSpace The Accelerator Selection Tool Network Map
About Us FAQ Calendar Pricing and Payment Policy Privacy Policy Terms of Service Agreement Contact Us
Industry News Impact Management Good Business Personal Finance Faith and investing Billionaires
Gender Lens Investing Women Rising in India
SDGs Climate Finance Clean Energy Innovative Finance Full Stack Capital Long-termism
Opportunity Zones Investing in place
Entrepreneurship Return on Inclusion Good Jobs Inclusive Fintech Creative economy Housing New Schooled Well Being People on the Move
Conservation Finance Farmer Finance Financing Fish
Blockchain/AI/IoT Urban Tech Food Tech Inclusive Fintech
Human Rights Democracy and Peace News and Information
Africa Asia Europe Latin America Middle East Oceania/Australia China Canada India United Kingdom United States Growth Markets
Subscribe Log In

Global Health Investment Fund clears a profit on voucher sale to Novo Nordisk

An innovative financing mechanism for drugs for neglected diseases is providing a return for impact investors.

Novo Nordisk, the Danish pharmaceutical giant, disclosed that it is the buyer of a “priority review voucher” from Medicines Development for Global Health, an Australian nonprofit that won U.S. Food and Drug Administration approval for moxidectin as a treatment for onchocerciasis, or river blindness.

With the approval came the voucher for an expedited FDA review of another drug. MDGH had estimated it could sell the voucher sold for $40 million, according to a report from Tideline, more than covering the $13 million required for the drug’s final development.

The Global Health Investment Fund, launched by the Gates Foundation and JPMorgan Chase, committed $10 million in 2015.

After a dozen deals, Global Health Investment Fund has overcome a rocky start

MDGH said “a significant portion” of the proceeds would go to fight river blindness, with the balance returned to investors in the global health fund, now known as Adjuvant Capital. Adjuvant is raising a second fund. 

MDGH’s Mark Sullivan said moxidectin “would have been left on the shelf” without the priority review voucher funding mechanism. 

You might also like...